COVID-19 — Coronavirus

Status
Not open for further replies.
GM SCOREBOARD TODAY

CASES 493 - UP FROM 481. NW TOTAL 1154 - UP FROM 1151. 43% of Total.

3 wks v 2 wks v last wk v today:- 1211 v 721 v 731 v 493 TODAY.

Still looking reasonably good despite slight signs here and there to be cautious.



Manchester 95 – down from 109. Total cases 32, 130. Weekly 981. Back under 1000 for all the GM weekly totals. A month or so ago most of GM boroughs were over 1000 a week. Pop score up 18 to 5812. Weekly Pop down 10 to 178.

Wigan 80 – up from 70. Total cases 17, 211. Weekly 634. Pop score up 25 to 5237. Weekly Pop stays at 193.

Oldham 61 - up from 38. Total cases 15, 220. Weekly 384 . Pop score up 26 to 6419. Most in GM today but again Blackburn with fewer cases rose more to 6732 – and is now 313 above Oldham as worst in UK Weekly Pop up 2 to 162.

Stockport 50 – up from 38, Total cases 10, 903. Weekly 346. Pop score up 17 to 3716. Weekly Pop down 3 to 118. (Cases lower than 7 days ago), Not a great day for Stockport - see below - but it goes down on this measure which shows how hard things are to call right now.

Bolton 49 - up from 47. Total cases 15, 611. Weekly 471, Pop score up 17 to 5429. Weekly Pop down 10 to 164.

Rochdale 41 - down from 46. Total cases 13, 159. Weekly 463. Pop score up 19 to 5917. Weekly Pop down 18 to 209.

Salford 37 up from 32. Total cases 13, 742. Weekly 350. Pop score up 14 to 5309. Weekly Pop down 6 to 135. .

Bury 36 – down from 46. Total cases 10, 191. Weekly 422. Pop score up 19 to 5336. Weekly Pop down 16 to 221. With Rochdale falling big they both push GM closer to no borough with a weekly pop over 200.

Trafford 26 - down from 27. Very low but not enough today! Total cases 8935. Weekly 198. Lowest in GM. And first in GM to go below 200 weekly since August. Pop score up 10 to 3764. Weekly Pop down 8 to 83. Lowest Weekly Pop in GM for three months. Gap to Stockport rises to 35 on weekly pop and cuts another 7 on Stockport's lead in chase for the overall Pop across the pandemic. Only 48 behind and will surely be Christmas number 1 now.

Tameside 18 – down from 28. Total cases 10, 709. Weekly 255. The race with Trafford is on for lowest weekly cases with Stockport here well off pace. Pop score up 8 to 4728. Lowest rise in a while here and best in GM today. Weekly Pop down 21 to 112. Best fall in GM today AND good enough to make Stockport's day even worse by overtaking it as closest to Trafford in the weekly Pop. Not much further to fall from here mind you!
 
Other watch areas:

Cheshire East 56 cases - up from 48. Total cases 9447. Pop score up 12 to 2459. Weekly Pop down 7 to 107.

Dartford 39 cases - down from 62. Pop score up 35 to 2510, Better day here.

Medway 197 cases - down from 216 - but enough to make it the second highest location in England behind only Birmingham in terms of case numbers today. Pop score up 71 - most in UK today. To 2916.

Medway is the number one problem area on the red list today.
 
I for one won't be taking the vaccine! I don't want Bill Gates tracking me while I'm trying to watch Mrs Browns Boys!!!!
 
sum of cases per 100k people, 7 moving window, up to 3rd Dec

seems to be a levelling off, from about the 26th Nov

covid_rates_NW.png
 
ayrshire_blue said:
Click to expand...

Some of that article reads like scaremongering to me. The FDA being notified 1 and 3 days later, maybe AZ were trying to work out what to report and why, is a time delay like that common? Also the bit about AZ having scant vaccine development experience? Really? No mention of Oxford Unis experience in this field, how do they fit in the world of vaccine developments? It comes across as negative and not very balanced admittedly in my very inexpert opinion. It would be very interesting to hear a take on it from the people on this forum with experience in this area? @03 March 2002 @roubaixtuesday and any others? Cheers
 
ayrshire_blue said:
Click to expand...

Very bizarre to be chastised for halting trials after what happened. I'm not sure what the FDA think they could have done in this situation?

Interestingly trials resumed everywhere but the US shortly after it was discovered that the adverse reaction wasn't related to the vaccine.

This was around the time Trump threw a paddy after being called out for calling their dead troops 'suckers' and 'losers'.
 
Churchlawtonblue said:
Some of that article reads like scaremongering to me. The FDA being notified 1 and 3 days later, maybe AZ were trying to work out what to report and why, is a time delay like that common? Also the bit about AZ having scant vaccine development experience? Really? No mention of Oxford Unis experience in this field, how do they fit in the world of vaccine developments? It comes across as negative and not very balanced admittedly in my very inexpert opinion. It would be very interesting to hear a take on it from the people on this forum with experience in this area? @03 March 2002 @roubaixtuesday and any others? Cheers
Click to expand...
The part about having scant vaccine development experience is laughable. Admittedly AZ's pipeline lies in so called CVRM medicines (Cardiovascular, Respiratory and Metabolic) but a simple bit of research would show AZ owns MedImmune (which doesn't operate autonomously and is fully incorporated into the AZ brand). They pump out in excess of 100m doses for the US alone.
 
Churchlawtonblue said:
Some of that article reads like scaremongering to me. The FDA being notified 1 and 3 days later, maybe AZ were trying to work out what to report and why, is a time delay like that common? Also the bit about AZ having scant vaccine development experience? Really? No mention of Oxford Unis experience in this field, how do they fit in the world of vaccine developments? It comes across as negative and not very balanced admittedly in my very inexpert opinion. It would be very interesting to hear a take on it from the people on this forum with experience in this area? @03 March 2002 @roubaixtuesday and any others? Cheers
Click to expand...
I agree. I skimmed the article and it definitely came across as politically motivated and nationalistic. It did not appear to identify that AZN did anything wrong. I am sure there are protocols that need to be followed to ensure the various parties around the world with responsibilities for governing the trials or other interests (including stock markets) are notified in the correct way. The article does not appear that any such protocols were breached.
 
03 March 2002 said:
The part about having scant vaccine development experience is laughable. Admittedly AZ's pipeline lies in so called CVRM medicines (Cardiovascular, Respiratory and Metabolic) but a simple bit of research would show AZ owns MedImmune (which doesn't operate autonomously and is fully incorporated into the AZ brand). They pump out in excess of 100m doses for the US alone.
Click to expand...
im guessing medlmmune is experienced in making many different types of vaccines?
 
Churchlawtonblue said:
Some of that article reads like scaremongering to me. The FDA being notified 1 and 3 days later, maybe AZ were trying to work out what to report and why, is a time delay like that common? Also the bit about AZ having scant vaccine development experience? Really? No mention of Oxford Unis experience in this field, how do they fit in the world of vaccine developments? It comes across as negative and not very balanced admittedly in my very inexpert opinion. It would be very interesting to hear a take on it from the people on this forum with experience in this area? @03 March 2002 @roubaixtuesday and any others? Cheers
Click to expand...

Squares with what I wrote yesterday, if rather more sensationally put.

The FDA wants full phase 3 data on the lower dose alone before deciding.

MHRA (and EMA) will probably approve using the data across both doses, but will need to choose which dose if that's the case.

No idea on the details, but a breakdown in relations with FDA seems very likely - there has to be a reason why they paused the trial for so much longer than any other agency.

AZ does, indeed have limited vaccine experience, just one (FLUMIST) on the market. Their part is more for clinical trials experience and manufacturing knowhow.

Note that even this article still expects approval in the US early next year.

My bottom line: that data in the lancet looks good and safe at either dose.
 
Status
Not open for further replies.
Unread Posts

Don't have an account? Register now and see fewer ads!

SIGN UP
Back
Top